ECHINACEA ANGUSTIFOLIA

N/A

Manufactured by Boiron

118 FDA adverse event reports analyzed

Last updated: 2026-04-15

About ECHINACEA ANGUSTIFOLIA

ECHINACEA ANGUSTIFOLIA is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Boiron. The most commonly reported adverse reactions for ECHINACEA ANGUSTIFOLIA include HYPOAESTHESIA, MUSCULAR WEAKNESS, PRURITUS, ABDOMINAL DISTENSION, ABDOMINAL PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ECHINACEA ANGUSTIFOLIA.

Top Adverse Reactions

HYPOAESTHESIA3 reports
MUSCULAR WEAKNESS3 reports
PRURITUS3 reports
ABDOMINAL DISTENSION2 reports
ABDOMINAL PAIN2 reports
DRY SKIN2 reports
FALL2 reports
HEADACHE2 reports
HOT FLUSH2 reports
LYMPHADENOPATHY2 reports
PARAESTHESIA ORAL2 reports
SPINAL OSTEOARTHRITIS2 reports
STRESS2 reports
URINARY TRACT INFECTION2 reports
URTICARIA2 reports
ABDOMINAL DISCOMFORT1 reports
ACUTE KIDNEY INJURY1 reports
ACUTE RESPIRATORY FAILURE1 reports
ALANINE AMINOTRANSFERASE INCREASED1 reports
ANAEMIA1 reports
ANGINA PECTORIS1 reports
ANXIETY1 reports
ASPARTATE AMINOTRANSFERASE INCREASED1 reports
ASTHENIA1 reports
BALANCE DISORDER1 reports
BICYTOPENIA1 reports
BLEPHARITIS1 reports
BLOOD GLUCOSE INCREASED1 reports
BLOOD PRESSURE INCREASED1 reports
CARDIAC ARREST1 reports
CEREBRAL VENTRICLE COLLAPSE1 reports
CEREBROVASCULAR ACCIDENT1 reports
CHEST DISCOMFORT1 reports
CHEST PAIN1 reports
CHOLELITHIASIS1 reports
COMPLETED SUICIDE1 reports
CONDITION AGGRAVATED1 reports
COUGH1 reports
DECREASED APPETITE1 reports
DIALYSIS DEVICE COMPLICATION1 reports
DIARRHOEA1 reports
DISTURBANCE IN ATTENTION1 reports
DRUG HYPERSENSITIVITY1 reports
DRUG INEFFECTIVE1 reports
DRUG INTERACTION1 reports
DRY MOUTH1 reports
DYSPEPSIA1 reports
DYSPNOEA EXERTIONAL1 reports
EPISTAXIS1 reports
EYELID BOIL1 reports
FAILURE TO THRIVE1 reports
FATIGUE1 reports
FUNGAL PERITONITIS1 reports
GAIT DISTURBANCE1 reports
GASTROINTESTINAL STROMAL TUMOUR1 reports
GASTROINTESTINAL WALL THICKENING1 reports
GASTROOESOPHAGEAL REFLUX DISEASE1 reports
GENERAL PHYSICAL HEALTH DETERIORATION1 reports
GLYCOSYLATED HAEMOGLOBIN INCREASED1 reports
HAEMORRHAGE1 reports
HYPERKALAEMIA1 reports
HYPERTENSIVE EMERGENCY1 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION1 reports
INSOMNIA1 reports
INSURANCE ISSUE1 reports
IRRITABLE BOWEL SYNDROME1 reports
LACTIC ACIDOSIS1 reports
LIP BLISTER1 reports
LIVER FUNCTION TEST ABNORMAL1 reports
MALAISE1 reports
METABOLIC ACIDOSIS1 reports
NAUSEA1 reports
NEOPLASM RECURRENCE1 reports
NERVE COMPRESSION1 reports
NON PITTING OEDEMA1 reports
OFF LABEL USE1 reports
OSTEOARTHRITIS1 reports
PARAESTHESIA1 reports
PERIORBITAL OEDEMA1 reports
PERITONITIS BACTERIAL1 reports
PLATELET COUNT DECREASED1 reports
PNEUMONIA1 reports
PRESYNCOPE1 reports
PRODUCT DOSE OMISSION ISSUE1 reports
PROSTATITIS1 reports
PYREXIA1 reports
RENAL HAEMORRHAGE1 reports
RIB FRACTURE1 reports
SEIZURE1 reports
SENSORY LOSS1 reports
SKIN EXFOLIATION1 reports
SKIN FISSURES1 reports
SKIN HAEMORRHAGE1 reports
SKIN WEEPING1 reports
SOMNOLENCE1 reports
SPINAL STENOSIS1 reports
STRESS URINARY INCONTINENCE1 reports
SUBDURAL HAEMATOMA1 reports
THERAPEUTIC RESPONSE DECREASED1 reports
THROMBOCYTOPENIA1 reports

Report Outcomes

Out of 22 classified reports for ECHINACEA ANGUSTIFOLIA:

Serious 54.5%Non-Serious 45.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female8 (53.3%)
Male7 (46.7%)

Reports by Age

Age 522 reports
Age 612 reports
Age 421 reports
Age 471 reports
Age 541 reports
Age 621 reports
Age 681 reports
Age 751 reports
Age 771 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with ECHINACEA ANGUSTIFOLIA?

This profile reflects 118 FDA FAERS reports that mention ECHINACEA ANGUSTIFOLIA. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for ECHINACEA ANGUSTIFOLIA?

Frequently reported terms in FAERS include HYPOAESTHESIA, MUSCULAR WEAKNESS, PRURITUS, ABDOMINAL DISTENSION, ABDOMINAL PAIN, DRY SKIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures ECHINACEA ANGUSTIFOLIA?

Labeling and FAERS entries often list Boiron in connection with ECHINACEA ANGUSTIFOLIA. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.